IPO-bound Intarcia hauls in $215M, and plans to add more; Peloton raises $52M round
With its highly touted diabetes drug/device ITCA 650 being set up for a promised launch late next year (if it’s approved), Intarcia has come up with a $215 million raise. And the private biotech, expected to line up for an IPO soon, says it will add even more cash to the kitty later this year. ITCA 650 is an implanted device that slowly oozes a reformulated version of exenatide. The biotech unicorn has already raised about a billion dollars.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.